222 related articles for article (PubMed ID: 28225311)
1. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).
van Beek DJ; Nell S; Pieterman CRC; de Herder WW; van de Ven AC; Dekkers OM; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
J Surg Oncol; 2019 Nov; 120(6):966-975. PubMed ID: 31401809
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne).
Vinault S; Mariet AS; Le Bras M; Mirallié E; Cardot-Bauters C; Pattou F; Ruszniewski P; Sauvanet A; Chanson P; Baudin E; Elias D; Menegaux F; Gaujoux S; Borson-Chazot F; Lifante JC; Caron P; Carrère N; Tabarin A; Laurent C; Klein M; Brunaud L; Niccoli P; Sebag F; Cadiot G; Kianmanesh R; Luu M; Binquet C; Goudet P
Ann Surg; 2020 Dec; 272(6):1094-1101. PubMed ID: 30585820
[TBL] [Abstract][Full Text] [Related]
4. One-Year Postoperative Mortality in MEN1 Patients Operated on Gastric and Duodenopancreatic Neuroendocrine Tumors: An AFCE and GTE Cohort Study.
Christou N; Mathonnet M; Gaujoux S; Cadiot G; Deguelte S; Kraimps JL; Lifante JC; Menegaux F; Mirallié E; Muscari F; Carnaille B; Pattou F; Sauvanet A; Goudet P
World J Surg; 2019 Nov; 43(11):2856-2864. PubMed ID: 31384998
[TBL] [Abstract][Full Text] [Related]
5. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
[TBL] [Abstract][Full Text] [Related]
6. Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.
van Beek DJ; Nell S; Verkooijen HM; Borel Rinkes IHM; Valk GD; ; Vriens MR; ;
Surgery; 2021 Apr; 169(4):963-973. PubMed ID: 33220975
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Patterns of Duodenopancreatic Neuroendocrine Tumors in Patients With Multiple Endocrine Neoplasia Type 1.
Hackeng WM; van Beek DJ; Kok ASM; van Emst M; Morsink FHM; van Treijen MJC; Borel Rinkes IHM; Dreijerink KMA; Offerhaus GJA; Valk GD; Vriens MR; Brosens LAA
Am J Surg Pathol; 2022 Feb; 46(2):159-168. PubMed ID: 34560682
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group.
Conemans EB; Brosens LAA; Raicu-Ionita GM; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Timmers HTM; Offerhaus GJ; Valk GD; Vriens MR
Pancreatology; 2017; 17(5):766-772. PubMed ID: 28811081
[TBL] [Abstract][Full Text] [Related]
9. Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients.
de Laat JM; Pieterman CR; van den Broek MF; Twisk JW; Hermus AR; Dekkers OM; de Herder WW; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Vriens MR; Valk GD
J Clin Endocrinol Metab; 2014 Sep; 99(9):3325-33. PubMed ID: 24915123
[TBL] [Abstract][Full Text] [Related]
10. The Management of Neuroendocrine Tumors of the Lung in MEN1: Results From the Dutch MEN1 Study Group.
van den Broek MFM; de Laat JM; van Leeuwaarde RS; van de Ven AC; de Herder WW; Dekkers OM; Drent ML; Kerstens MN; Bisschop PH; Havekes B; Hackeng WM; Brosens LAA; Vriens MR; Buikhuisen WA; Valk GD
J Clin Endocrinol Metab; 2021 Jan; 106(2):e1014-e1027. PubMed ID: 33135721
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Outcomes for Patients with Multiple Endocrine Neoplasia Type 1 and Duodenopancreatic Neuroendocrine Neoplasms.
Liu JB; Cai J; Dhir M; Paniccia A; Zureikat AH; Ramonell KM; McCoy KL; Carty SE; Yip L
Ann Surg Oncol; 2022 Nov; 29(12):7808-7817. PubMed ID: 35963905
[TBL] [Abstract][Full Text] [Related]
12. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors.
Kfir SK; Halperin R; Percik R; Uri I; Halpern N; Shlomai G; Laish I; Tirosh A; Tirosh A
Horm Metab Res; 2021 May; 53(5):319-325. PubMed ID: 33878789
[TBL] [Abstract][Full Text] [Related]
13. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.
Ito T; Igarashi H; Uehara H; Berna MJ; Jensen RT
Medicine (Baltimore); 2013 May; 92(3):135-181. PubMed ID: 23645327
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.
Chiloiro S; Lanza F; Bianchi A; Schinzari G; Brizi MG; Giampietro A; Rufini V; Inzani F; Giordano A; Rindi G; Pontecorvi A; De Marinis L
Endocrine; 2018 May; 60(2):362-367. PubMed ID: 28567607
[TBL] [Abstract][Full Text] [Related]
15. Duodenal, ampullary, and pancreatic neuroendocrine tumors: Oncologic outcomes are driven by tumor biology and tissue of origin.
Schmocker RK; Wright MJ; Ding D; Javed AA; Cameron JL; Lafaro K; Burns WR; He J; Wolfgang CL; Burkhart RA
J Surg Oncol; 2021 Feb; 123(2):416-424. PubMed ID: 33125737
[TBL] [Abstract][Full Text] [Related]
16. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.
Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Murage E; Wu R; Dennison JB; Krishna H; Peterson CB; Lozano G; Zhao H; Do KA; Halperin DM; Agarwal SK; Blau JE; Del Rivero J; Nilubol N; Walter MF; Welch JM; Weinstein LS; Vriens MR; van Leeuwaarde RS; van Treijen MJC; Valk GD; Perrier ND; Hanash SM
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4969-e4980. PubMed ID: 34318891
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1.
Lopez CL; Waldmann J; Fendrich V; Langer P; Kann PH; Bartsch DK
Langenbecks Arch Surg; 2011 Dec; 396(8):1187-96. PubMed ID: 21805182
[TBL] [Abstract][Full Text] [Related]
18. Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up.
Giudici F; Cavalli T; Giusti F; Gronchi G; Batignani G; Tonelli F; Brandi ML
World J Surg; 2017 Sep; 41(9):2312-2323. PubMed ID: 28429092
[TBL] [Abstract][Full Text] [Related]
19. Metastasectomy of neuroendocrine tumors in patients with multiple endocrine neoplasia type 1.
Dy BM; Que FG; Thompson GB; Young WF; Rowse P; Strajina V; Richards ML
Am J Surg; 2014 Dec; 208(6):1047-53; discussion 1052-3. PubMed ID: 25440487
[TBL] [Abstract][Full Text] [Related]
20. The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis.
Wang S; Zhang J; Liu S; Zhang J
Medicine (Baltimore); 2019 Nov; 98(44):e17773. PubMed ID: 31689842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
